This is a settled corner of medicine: treatment works, and the binding constraint is detection. A comprehensive eye exam runs $50 to $200, is often covered by insurance, and takes under an hour. The exam itself is the whole action — once a year or every couple, depending on age and risk. The vision you lose in years you should have been on the calendar does not come back.
How the disease actually works
The eye constantly makes a clear fluid called aqueous humor and constantly drains it through a sieve-like tissue near the front called the trabecular meshwork. In open-angle glaucoma the sieve clogs gradually — the angle between iris and cornea stays anatomically open (hence "open-angle"), but flow resistance climbs Weinreb 2014. Fluid backs up. Pressure inside the eye rises. That pressure presses on the back of the eye where the optic nerve — the cable carrying every visual signal from your retina to your brain — exits through a perforated plate of collagen called the lamina cribrosa. The nerve fibers get pinched and starved. They die. They do not grow back.
The first place the damage shows up is the periphery, in patterns the brain papers over for years: arcs of missing vision above and below the gaze, a step in the nasal field, a paracentral blind spot you'd never spot on your own. Late in the disease the central vision goes too. By the time someone notices a chunk of their world missing, the nerve fibers that used to map it are already gone.
Eye pressure is the cause of glaucoma the way speeding is the cause of crashes — usually, mostly, on average, but not always. Roughly a third of open-angle glaucoma cases worldwide happen at eye pressures inside the "normal" range, called normal-tension glaucoma; the mechanical properties of that perforated plate of collagen and the blood supply to the optic nerve matter alongside pressure itself Tham 2014. But pressure is the only lever the treatment can pull, and pulling it works.
Does treatment actually work
This is one of the most replicated treatment claims in adult medicine. Six trials, four decades, every major eye-care guideline aligned: lowering eye pressure slows glaucomatous vision loss by roughly half.
What no trial has shown: that anything reverses damage already done. Treatment slows the rate of further loss. It does not give back the visual field that's already gone. That asymmetry is what makes detection the load-bearing part of the whole problem.
Who's actually at higher risk
Risk isn't evenly distributed across adults. Five factors do most of the work:
- Age. Prevalence is about half a percent in adults aged 40 to 49 and roughly seven percent by the late 70s Tham 2014. A 75-year-old is roughly fifteen times as likely to have glaucoma as a 45-year-old.
- African ancestry. Glaucoma is roughly four times as common in adults of African descent as in adults of European descent, with onset about a decade earlier and faster progression once diagnosed. The Baltimore Eye Survey found around 5% of Black American adults with glaucoma at exam, against about 1% of White American adults across age strata Sommer 1991.
- Family history. A parent or sibling with glaucoma raises your risk roughly three- to four-fold over the population baseline; siblings in particular run something like a 10% lifetime risk.
- Thin corneas and high myopia. A thin cornea (under 555 micrometres; measured during the exam) and severe nearsightedness both independently raise risk and were identified in the OHTS prediction model Kass 2002.
- Previous noted elevated eye pressure. Even if past exams just said "borderline" or "watch this," you're in a higher-risk pool.
If two or more of these apply to you, the higher-frequency exam cadence in the section below applies from your 40s, not your 60s.
If you keep skipping the exam
The disease is silent, so the early years feel like nothing. Years before vision loss is something you'd report to a doctor, the periphery starts thinning — a friend at a barbecue waves at you and you turn before you realise you sensed it; you bump into the corner of a doorway you've passed a thousand times. The brain absorbs it as you-being-tired.
By your late 60s or early 70s, if the disease has been advancing untreated, the pattern is recognisable in retrospect. The book you read every night gets harder to hold at the right angle. You stop driving at night first — too many headlights from the sides you can't quite track. Then you stop driving in the city. Then a grandchild crosses your kitchen and you don't see them. Your spouse starts handling the stairs ahead of you. Falls become a thing that happens, and one of them is the one that breaks a hip Ramulu 2009.
What people around you notice first is that you're quieter at family dinners — across the table is the bit of vision that's already gone, and reading lips at a distance is harder. Then the calls from your kids start checking whether you'd like to move closer to one of them. None of this needs the extreme case to land. Globally, glaucoma is the leading cause of permanent blindness; in 2020 it accounted for an estimated 3.6 million cases of blindness, and the projected number of people with the disease in 2040 is 111.8 million GBD 2020Tham 2014. The vast majority of those outcomes are people who never got the routine exam, or who got it once and never came back.
The asymmetry that does the work: the exam is an hour, every couple of years. The vision you lose if you skip it does not return.
What the exam looks like
A glaucoma-relevant eye exam isn't the eye chart at the DMV. It's a comprehensive dilated exam done by an optometrist or ophthalmologist, lasting under an hour. Five things get done; any one of them in isolation is unreliable, but together they sort you cleanly.
- Eye-pressure measurement. Either a tiny tip touched gently to the cornea after a numbing drop (the reference standard), or an air-puff machine. A single reading isn't definitive — pressure swings a few mmHg across the day — but it's the number treatment targets.
- A look at the optic nerve. Drops dilate your pupils; the doctor shines a light through and looks at the disc where the nerve exits the back of the eye. A "cupped" disc with thinned tissue at the edges is the visible signature.
- An OCT scan of the nerve fibre layer. A non-contact infrared scan that measures the thickness of the nerve fibres around the optic nerve to the micrometre. This typically catches the damage years before a visual-field test can AAO PPP 2020.
- A visual-field test. You stare into a bowl and click a button when you see flickers of light at the edges. Tedious. Roughly 8–10 minutes per eye. Subjective enough that the doctor will repeat it to confirm any defect.
- Gonioscopy. A mirrored lens placed on the eye to look at the drainage angle. Confirms the angle is anatomically open (the disease this entry is about) rather than closed (a different disease with a different treatment path).
Total cost in the United States: typically $50 to $200 out of pocket without insurance, and often partially or fully covered by vision or medical insurance from age 40 onward. The two highest-value pieces — the OCT plus the dilated look at the optic nerve — are the parts a primary-care office generally can't do, which is why this lives with eye specialists.
When to get it
Cadence rises with age and with risk. The American Academy of Ophthalmology's recommendation for adults without known risk factors AAO Comprehensive Adult Medical Eye Evaluation PPP 2020:
The cadence isn't arbitrary. Population data show glaucoma prevalence rising from roughly half a percent in your 40s to about seven percent in your 70s Tham 2014; the exam frequency is calibrated so that new disease gets caught within a window where treatment still has decades to work.
What most people get wrong
- "My eyes feel fine, so I don't need to worry." Open-angle glaucoma is painless and asymptomatic until late. Most damage happens in the periphery — where the brain is good at smoothing over missing pixels — and people with substantial measurable field loss are often unaware of it. Roughly half the people who have glaucoma in countries like the US don't yet know Quigley & Broman 2006.
- "If my eye pressure is normal, I'm in the clear." Roughly a third of open-angle glaucoma worldwide happens at "normal" pressures (under 21 mmHg on a single reading) Tham 2014. Pressure also varies through the day. A single number is a snapshot; the optic-nerve exam and OCT scan are what actually catch the disease.
- "I read screening isn't recommended." The 2022 US Preventive Services Task Force statement says the evidence isn't strong enough to recommend that primary-care doctors screen with their own tools, which are limited USPSTF 2022. It does not say the comprehensive dilated exam at an eye specialist's office isn't valuable — that's where actual detection happens, and the American Academy of Ophthalmology still recommends it on the cadence above.
- "If I'm diagnosed and take the drops, the lost vision will come back." No. Treatment slows the rate of further loss; it does not regenerate dead optic-nerve fibres. The case for catching glaucoma early is that you protect what's still there. And the drops only work if you actually take them — when researchers monitored a group of glaucoma patients with electronic dosing aids, knowing they were being watched, nearly half still used their drops less than 75% of the time Friedman 2009.
What else to look at
Three adjacent topics that ride on the same exam or sit next door:
- The comprehensive eye exam itself — the same appointment screens for cataracts, age-related macular degeneration, diabetic retinopathy, and refractive change. None of those are open-angle glaucoma, but the visit covers them.
- Angle-closure glaucoma — a different, acute, painful presentation that's a true ocular emergency. Most relevant for high-risk anatomy (small eyes, far-sighted adults, certain Asian populations); rare enough that the general screening cadence already covers it.
- Diabetes — diabetes modestly raises glaucoma risk and produces its own retinal disease; the two detection pathways overlap and both benefit from a long-term relationship with an eye-care clinician.
- — The exam that catches glaucoma early is exactly this comprehensive check — eye pressure plus a careful look at the optic nerve.
- — Diabetes adds its own silent eye damage on top of glaucoma risk — if you're diabetic, the yearly dilated exam covers both.
- — The Amsler grid catches a different silent eye disease — glaucoma hides in the periphery and needs the in-clinic exam.
- — Glaucoma steals vision with no warning at all; sudden flashes, a curtain, or a grey patch are the opposite case — an emergency, not a slow creep.
Substance and claimed effects
Primary open-angle glaucoma (POAG) is a chronic, painless, progressive optic neuropathy: retinal ganglion cells die over years to decades, the optic nerve head excavates ("cups"), and the visual field thins from the periphery inward. The angle between iris and cornea remains anatomically open — distinguishing it from angle-closure glaucoma, which presents as a painful ocular emergency — and aqueous-humor outflow is impaired at the trabecular meshwork, raising intraocular pressure (IOP) in most but not all eyes Weinreb 2014. The conjunction of features the entry covers: prevalence and burden (the world's leading cause of irreversible blindness GBD 2020); pathophysiology (IOP, optic nerve head biomechanics, ganglion cell loss); detection through the comprehensive dilated eye exam (tonometry, optic disc and retinal nerve fiber layer assessment, visual field testing, gonioscopy, central corneal thickness); risk factors (age, African ancestry, family history, elevated IOP, thin corneas, high myopia); the IOP-lowering treatment paradigm (prostaglandin analogs, selective laser trabeculoplasty, incisional surgery); and the felt and functional consequences of late detection (peripheral then central vision loss, driving cessation, falls, depression). The claimed effect underwriting the entry's action is detection-by-exam: catching POAG before clinically significant field loss preserves lifetime vision EMGT 2002UKGTS 2015.
Evidence by addressing question
Mechanism
Aqueous humor is produced by the ciliary epithelium and exits the anterior chamber through two pathways: the trabecular meshwork → Schlemm canal → episcleral veins (conventional, ~85% of outflow) and the uveoscleral route (unconventional, ~15%) Weinreb 2014. In POAG the conventional outflow facility falls; production is unchanged; IOP rises (population mean ~16 mmHg, "high-tension" POAG typically >21 mmHg). Elevated IOP exerts mechanical and shear stress on the lamina cribrosa — the sieve-like collagen plate the optic nerve axons traverse on exit from the eye — and impairs axoplasmic transport, triggering retinal ganglion cell (RGC) apoptosis. Axonal loss is the irreversible step; once an RGC dies, it does not regenerate.
Two mechanistic facts complicate the IOP-centric story. First, a substantial fraction of POAG occurs at IOPs within the statistically normal range (normal-tension glaucoma, NTG) — perhaps a third of POAG in Western cohorts and a majority in some East Asian populations Tham 2014. Second, the population-level relationship between IOP and POAG is continuous, not threshold: in the Baltimore Eye Survey, POAG prevalence rose monotonically with IOP from 14 mmHg upward, and many eyes with IOP above 21 mmHg never developed disease Sommer 1991. Vascular factors (nocturnal hypotension, ocular perfusion pressure), lamina cribrosa biomechanics (thin or compliant connective tissue), and genetic susceptibility (MYOC, OPTN, TBK1, GWAS-identified loci) all modulate the IOP-to-axon-loss conversion. Trial-derived consensus: IOP is the only modifiable risk factor with proven causal weight, even when baseline IOP is "normal" CNTGS 1998.
Evidence
Six trials anchor modern POAG management; together they establish IOP lowering as the only evidence-based intervention to slow progression, across the spectrum from ocular hypertension to advanced disease.
- OHTS (Ocular Hypertension Treatment Study; Kass 2002, 20-year follow-up Kass 2021). 1,636 adults with untreated IOP 24–32 mmHg and normal optic discs/fields randomised to medical IOP lowering vs observation. Treatment halved the 5-year cumulative incidence of POAG (4.4% vs 9.5%); the 20-year cumulative incidence was 45.6% across the cohort, with 25% developing visual field loss Kass 2002Kass 2021. The trial generated the standard risk-prediction model (age, IOP, central corneal thickness, vertical cup-disc ratio, pattern standard deviation) used to triage ocular hypertensives for treatment.
- EMGT (Early Manifest Glaucoma Trial; Heijl 2002). 255 newly-diagnosed open-angle glaucoma patients randomised to argon laser trabeculoplasty plus betaxolol vs no initial treatment. Mean IOP fell ~5 mmHg (25%) in the treated arm. Progression: 45% treated vs 62% controls over 6 years (
p<0.007); median time to progression delayed 18 months Heijl 2002. Each 1 mmHg lower IOP corresponded to a ~10% reduction in progression risk — a dose-response that has become a clinical heuristic. - CNTGS (Collaborative Normal-Tension Glaucoma Study; 1998). NTG patients randomised to 30% IOP reduction vs no treatment. Progression: 12% treated vs 35% controls. Confirmed that IOP lowering benefits even eyes with baseline IOP <21 mmHg, though 65% of untreated NTG eyes remained stable through follow-up — a heterogeneity that complicates the universal-treatment case for NTG CNTGS 1998.
- AGIS (Advanced Glaucoma Intervention Study; 2000). In advanced POAG, eyes maintaining IOP
<18 mmHgat every visit had minimal field progression; the lowest-IOP subgroup (mean ~12 mmHg) showed near-zero mean visual field change over 8 years AGIS 2000. Established the principle of progressively lower IOP targets as disease severity advances. - UKGTS (UK Glaucoma Treatment Study; Garway-Heath 2015). 516 newly-diagnosed open-angle glaucoma patients, the first placebo-controlled RCT of a topical IOP-lowering drug. Latanoprost vs vehicle. Visual field preservation hazard ratio 0.44 (95% CI 0.28–0.69,
p=0.0003); mean IOP reduction 3.8 mmHg in the treatment arm Garway-Heath 2015. Closed the placebo-comparator gap that earlier trials had left open. - LiGHT (Laser in Glaucoma and Ocular Hypertension; Gazzard 2019, 6-year update 2022). 718 treatment-naive POAG/OHT patients randomised to selective laser trabeculoplasty (SLT) vs eye drops as first-line. At 3 years, 74% of SLT eyes were drop-free with target IOP achieved; at 6 years, SLT-first patients required less incisional surgery and less cataract surgery than the drops-first arm Gazzard 2019. Changed UK NICE and emerging international guidelines to position SLT as a viable first-line.
Across the trials the consistent finding is that IOP lowering of 20–30% slows progression by roughly half over 5–6 years; the effect compounds across decades. No intervention has been shown to reverse existing damage or independently neuroprotect axons; every guideline-endorsed therapy works by lowering IOP AAO PPP 2020.
Practicalities (how detection actually works)
A comprehensive dilated eye examination integrates several tests; no single one defines diagnosis. Components:
- Tonometry. Goldmann applanation tonometry is the reference standard; non-contact ("air-puff") and rebound tonometers are common in primary care. Single-visit IOP is a weak diagnostic instrument — IOP varies diurnally by ~3–5 mmHg in normal eyes and more in glaucomatous eyes — but it is the modifiable target and is therefore measured at every visit.
- Optic disc / nerve fiber layer evaluation. Direct ophthalmoscopy or slit-lamp biomicroscopy assesses cup-to-disc ratio, neuroretinal rim notching, disc hemorrhages, and peripapillary atrophy. Optical coherence tomography (OCT) quantifies retinal nerve fiber layer (RNFL) and macular ganglion cell complex thickness with micrometer precision; RNFL thinning typically precedes detectable visual field defect by years (a frequently-cited estimate is ~6 years in OCT-monitored cohorts) AAO PPP 2020.
- Visual field testing. Standard automated perimetry (Humphrey 24-2 or 30-2) detects characteristic glaucomatous defects — nasal step, paracentral scotoma, arcuate defect respecting the horizontal midline — but is subjective, learning-dependent, and noisy; multiple confirmed defects are needed before treatment.
- Gonioscopy. Mirror-lens view of the iridocorneal angle to confirm open-angle anatomy and exclude angle-closure or secondary mechanisms.
- Central corneal thickness (pachymetry). Thinner corneas falsely lower the Goldmann reading and were independently identified as a POAG risk factor in OHTS Kass 2002.
Guideline cadence (AAO 2020 Comprehensive Adult Medical Eye Evaluation PPP): asymptomatic adults without risk factors — baseline exam at age 40, then every 2–4 years (40–54), every 1–3 years (55–64), every 1–2 years (65+) AAO Comprehensive Eye Eval 2020. Adults with risk factors (family history, African or Hispanic ancestry, diabetes, prior elevated IOP) warrant more frequent examination starting earlier. The 2022 USPSTF I statement on primary-care glaucoma screening reflects the gap between primary-care infrastructure (tonometry, fundoscopy uncommon in PCP offices) and ophthalmic infrastructure (where the exam is routine and not in question) USPSTF 2022; it does not contradict the AAO's specialist-exam cadence.
Audience and risk stratification
Major established risk factors for POAG:
- Age. Prevalence rises from ~0.5% in adults aged 40–49 to ~7% in adults aged 70–79 in pooled global data Tham 2014. The Tham meta-analysis pooled 50 population studies and 3,770 POAG cases.
- African ancestry. POAG prevalence in adults of African descent is roughly 4× that in adults of European descent in age-matched cohorts; in the Baltimore Eye Survey, prevalence in Black Americans was ~5% vs ~1% in White Americans across age strata, with onset 10 years earlier Sommer 1991. African ancestry also predicts more aggressive progression.
- Family history. First-degree relatives carry roughly 3–9× the population risk depending on the cohort; sibling risk in particular runs ~10% lifetime in some studies.
- IOP. Risk rises continuously above ~15 mmHg; risk at IOP 25 mmHg is roughly 10–15× that at IOP 15 mmHg in untreated cohorts.
- Central corneal thickness <555 μm. OHTS-identified independent predictor of conversion from ocular hypertension to POAG.
- High myopia. Axial length >26 mm increases POAG risk roughly 2–3×; mechanism likely related to lamina cribrosa thinness and biomechanics.
- Diabetes mellitus. Modest independent risk increase (RR ~1.4 in pooled cohorts).
Misconceptions
Several beliefs distort lay and even primary-care understanding:
- "Glaucoma causes eye pain." Acute angle-closure does. POAG, the dominant form, is asymptomatic until field loss is advanced. The conflation explains both undertesting in asymptomatic adults and over-reassurance ("my eyes feel fine") in diagnosed patients who lapse from follow-up.
- "If the IOP is normal, you don't have glaucoma." The Beaver Dam and Baltimore Eye surveys established that roughly half of POAG cases have a single-visit IOP <21 mmHg Sommer 1991; diurnal variation, prior topical steroid use, and normal-tension subtypes all defeat the single-reading rule.
- "Vision lost can be recovered." No therapy reverses RGC death. Treatment slows the rate of loss; it does not restore visual field.
- "USPSTF says screening doesn't work." The 2022 I statement is about primary-care screening with the tools available in primary care; it explicitly does not address the dilated specialist exam, which is the operational definition of detection.
Failure modes and adherence
The most common reason treatment fails in already-diagnosed patients is non-adherence to drops. Friedman 2009 monitored 196 patients with electronic dosing aids despite knowing they were being observed: 45% used drops less than 75% of the time over 3 months Friedman 2009. Drivers: forgetfulness, instillation difficulty (older patients, arthritis), surface irritation, cost, and lack of felt feedback — patients cannot perceive whether the drop is working, and progression is invisible until field loss becomes symptomatic. The LiGHT trial's case for SLT as first-line rests partly on this: laser bypasses the daily-adherence problem entirely Gazzard 2019.
Stakes (the felt-experience forecast)
Untreated or undertreated POAG progresses asymmetrically and slowly. Early functional consequences appear before patients consciously notice field loss: increased frequency of bumping objects, slower reading speed, difficulty with low-contrast tasks, and increased fall risk in older adults Ramulu 2009. Once bilateral moderate field loss (mean deviation worse than –6 dB) is established, driving cessation becomes likely; in US Medicare cohorts, advanced glaucoma roughly doubles the odds of depression and increases the odds of nursing-home placement. At the population level, glaucoma was responsible for an estimated 3.6 million cases of blindness globally in 2020 (8.4% of all blindness) GBD 2020; it is the leading cause of irreversible blindness worldwide and projected to affect 111.8 million people by 2040 Tham 2014.
Out-of-scope (for forward pointers)
Angle-closure glaucoma (different mechanism, acute presentation, requires emergency response); secondary glaucomas (pigmentary, pseudoexfoliative, neovascular, steroid-induced); congenital glaucoma; cataracts and age-related macular degeneration (other major causes of adult vision loss with their own detection pathways); diabetic retinopathy (overlapping screening but distinct pathology); the full comprehensive dilated eye exam as a separate entry candidate covering AMD, retinal disease, refractive change, and ocular surface health.
Credibility range
Optimist case
POAG is the catalogue's clearest example of a slow, silent disease where targeted screening + a cheap effective intervention bends the natural history. Six landmark RCTs across the disease spectrum converge: IOP lowering halves progression. Generic latanoprost costs under $10/month in the United States and is widely available; SLT is single-visit, drop-free, and increasingly first-line. The detection pathway exists, the equipment is universal in ophthalmology and optometry practices, and the cost of an exam (around $50–200 in the US, often covered) is trivial against the cost of late-stage blindness. Population-level data show that countries with high specialist-exam access (Japan, much of Europe) detect glaucoma at earlier disease stages than countries without. The intervention works; the binding constraint is detection. An adult who gets the recommended specialist exam at age 40, every 2–4 years thereafter, and complies with treatment if diagnosed is overwhelmingly likely to keep functional vision through their ninth decade Kass 2021.
Skeptic case
The screening case has known cracks. USPSTF gave glaucoma screening an I statement in 2022, citing weak direct evidence that primary-care detection improves patient-important outcomes USPSTF 2022. The OHTS 20-year data underscore that 30% of "ocular hypertensives" never developed POAG even untreated, raising over-diagnosis and over-treatment concerns; cataract was a documented harm of treatment in CNTGS (38% vs 14%) CNTGS 1998. Approximately half of glaucoma cases in developed countries are undetected, but detected cases also include false positives, and the cost-effectiveness of universal vs targeted screening is contested. NTG remains mechanistically incomplete — 65% of CNTGS untreated controls did not progress, suggesting either disease heterogeneity or measurement noise. Adherence in the real world undermines trial-based projections: Friedman 2009 found drop adherence below 75% in nearly half of monitored patients Friedman 2009, and the gap between intent-to-treat trial results and real-world preservation is likely substantial.
Author's call
The detection-paradigm case is strong and the treatment-efficacy case is among the strongest in ophthalmology — both anchored in multiple decade-long RCTs. The skeptic objections are real but operate at the margins: they argue against universal primary-care screening, not against the specialist eye exam, and they argue for better risk stratification before treating ocular hypertension, not against treating diagnosed POAG. The entry lands on the optimist side with two honest caveats: detection cadence should be risk-stratified (higher-risk adults — African ancestry, family history, prior elevated IOP — start earlier and go more often), and the prescription-only nature of treatment means a clinician relationship is required throughout. Scores high evidence (multiple RCTs, guideline-aligned), low controversy (treatment paradigm has broad consensus; debate is on screening logistics, not on whether glaucoma can be detected or whether IOP lowering works).
Stakeholder and incentive map
- Ophthalmology + optometry. Professional incentive aligned with detection and management — fee-for-service exams, OCT throughput, drop / SLT / surgical revenue. The dominant editorial voice (AAO Preferred Practice Patterns) is also the most authoritative.
- Pharmaceutical industry. Active in second- and third-line drops (combination products, preservative-free, newer classes like rho kinase inhibitors); generic latanoprost dominates first-line. Less commercial pressure on detection than on drop switching.
- Primary care + public health bodies. USPSTF I statement reflects PCP-tool limitations; CDC and the National Eye Institute messaging emphasises specialist-exam access, particularly in higher-risk populations.
- Glaucoma research foundations / patient advocacy. Glaucoma Research Foundation, World Glaucoma Association push earlier detection and adherence aids; community signal here is consistent with the trial evidence.
- Counter-incentives. Patients with no symptoms see no felt return on the exam or the drops; insurance gaps in vision coverage push exams off-schedule for some adults; over-diagnosis critics (a small but published minority) argue for tighter referral criteria.
Population variability
- Age. Risk rises ~10× from age 40 to age 80. Screening cadence accordingly tightens.
- Ancestry. Adults of African descent have ~4× the prevalence of adults of European descent and earlier onset; Asian populations show higher proportions of NTG and angle-closure variants Tham 2014.
- Family history. Roughly triples to quadruples risk in first-degree relatives.
- Sex. Globally men have ~1.3× the POAG prevalence of women; for angle-closure the ratio reverses.
- Refractive status. High myopia raises POAG risk and complicates structural assessment (large discs, peripapillary atrophy).
- Comorbidity. Diabetes (modest increase), prior systemic or topical steroid use (steroid-induced IOP rise), prior ocular trauma or surgery.
- Adherence variability. Older patients, those with arthritis, those without a caregiver, and those with depression have lower drop adherence — a meaningful determinant of real-world outcomes Friedman 2009.
Knowledge gaps
- Neuroprotection independent of IOP. Multiple trials of memantine, brimonidine (as neuroprotectant), and others have failed or shown ambiguous benefit. No FDA-approved IOP-independent therapy exists.
- Normal-tension glaucoma mechanism. Vascular vs biomechanical vs genetic weighting is unresolved; nocturnal blood-pressure dipping and obstructive sleep apnea contributions are areas of active study.
- Optimal screening strategy. Cost-effectiveness of universal vs risk-targeted vs technology-enabled (OCT-screening, AI fundus interpretation) approaches; USPSTF I statement reflects this gap.
- Real-world adherence interventions. Reminder systems, sustained-release implants (bimatoprost SR), and SLT-first strategies are improving but adherence remains the largest gap between trial efficacy and real-world effectiveness.
- Genetic risk stratification. Polygenic risk scores are emerging in research cohorts but have not entered clinical practice at scale.
Scope. The brief named open-angle glaucoma specifically, plus detection, IOP measurement, and visual-field / long-term-vision effects. The article covers all four. Angle-closure glaucoma, secondary glaucomas (pigmentary, pseudoexfoliative, neovascular, steroid-induced), and congenital glaucoma are out of scope and would warrant their own entries.
Action choice. Set test rather than do or decide. The load-bearing recommendation here is the periodic specialist exam; treatment selection (drops vs SLT vs surgery) is for diagnosed patients and rides on clinician input — covered in the body for completeness but not the entry's primary ask.
Cadence. Set yearly. The AAO cadence is age-stratified (every 2–4 years from 40, tightening to every 1–2 years from 65); yearly is the closest single token in the controlled vocabulary. The protocol callout in the body carries the actual age-stratified schedule.
Rating decisions.
- focus, mood, longevity all scored 1. These are conditional benefits — they accrue to the fraction of readers who would develop POAG and let it progress. ~3% of adults aged 40–80 globally have POAG Tham 2014, and the OHTS 20-year cohort showed 45.6% cumulative incidence in ocular hypertensives Kass 2021. Population-weighted effect is modest; within-affected effect is real. Scored 1 to honour both ends honestly.
- health_short_term scored 0. No felt change from getting screened. The benefit is preserving future state, not improving present state.
- evidence scored 5. Six landmark RCTs (OHTS, EMGT, CNTGS, AGIS, UKGTS, LiGHT) plus aligned AAO Preferred Practice Pattern. Easily clears the "name 2+ rigorous trials" bar.
- controversy scored 1. Active debate at the margins (USPSTF 2022 I statement on primary-care screening; over-diagnosis concerns around ocular hypertension treatment), but no paradigm-level dispute on detection or treatment.
No payoff section. For a silent disease where the action is "get tested," the payoff is "you don't lose vision you wouldn't have noticed losing for years" — hard to write authentically without slipping into the felt-experience-of-not-losing-something register, which reads thin. stakes carries the activation load; the asymmetry framing at the end of stakes ("the vision you lose if you skip it does not return") is the entry's de facto payoff inversion.
Future-link candidates.
- Comprehensive eye exam — as its own entry, covering cataracts, AMD, diabetic retinopathy detection. Currently signposted in
out-of-scope. - Angle-closure glaucoma — different mechanism, emergency presentation, narrower population. Genuine separate-entry candidate.
- Age-related macular degeneration — leading cause of central vision loss in older adults; complementary to glaucoma's peripheral pattern.
- Diabetic retinopathy — shares the dilated-exam detection pathway; tightly linked to diabetes management.
Hard call on inline trial vocabulary. The evidence-section science callout names six trials by acronym and one-line summary. The trial labels (OHTS, EMGT, etc.) are jargon by friend-test standards, but their cumulative weight is the point of the section, and the callout flag earns the scan-skip option. Each line still gives a plain-language summary, not a trial-design report.
Open-Angle Glaucoma
A comprehensive specialist eye exam runs roughly $50–200 in the United States, frequently covered under vision or medical insurance for adults 40+. Generic latanoprost, the first-line drug if treatment is needed, costs under $10/month. Selective laser trabeculoplasty is a one-off procedure typically covered when indicated (Gazzard 2019).
Recommended cadence is one specialist exam every 1–4 years depending on age (AAO 2020), each appointment under an hour. If diagnosed, daily eye-drop instillation or a single SLT session. Total effort burden minimal for screening; modest for ongoing treatment.
Six landmark RCTs across the disease spectrum — OHTS, EMGT, CNTGS, AGIS, UKGTS, LiGHT — consistently show that lowering intraocular pressure halves the rate of glaucomatous progression, with dose-response of roughly 10% lower progression risk per 1 mmHg (Heijl 2002, Garway-Heath 2015, Gazzard 2019, Kass 2021). Guideline-aligned (AAO 2020 PPP).
Vision loss in older adults is an independent risk factor for falls and hip fractures, both of which carry meaningful one-year mortality (Ramulu 2009). Early detection avoids that downstream cascade. Population-weighted effect is modest because only ~3% of adults 40–80 have POAG (Tham 2014), but the within-affected effect is real.
Glaucoma progressively erodes peripheral then central visual field; bilateral moderate field loss measurably slows reading and disrupts visual deep work (Ramulu 2009). Catching the disease early preserves the visual substrate cognitive work depends on. Modest at population scale because most readers will not have glaucoma; meaningful within the at-risk fraction.
Advanced bilateral glaucoma roughly doubles the odds of depression in Medicare cohorts and is associated with driving cessation, social withdrawal, and nursing-home placement (Ramulu 2009). Detection preserves the independence whose loss drives those psychological outcomes.